Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Open accessAbstract
Significance: The major stumbling block in the use of checkpoint inhibitors for cancer treatment is the severe autoimmunity that often results. In this study, we found the toxicity of a checkpoint blockade antibody can be ameliorated via administration of Bifidobacterium , a widely available probiotic. These results suggest that it may be possible to mitigate the autoimmunity caused by anti–CTLA-4 and perhaps other checkpoint inhibitors by manipulating gut microbiota.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mouse models have verified that Bifidobacteria, Bacteroides fragilis, and Burkholderia cepacia can ameliorate intestinal immunopathology in the context of anti-CTLA-4 therapy.
“Mouse models have verified that Bifidobacteria, Bacteroides fragilis, and Burkholderia cepacia can ameliorate intestinal immunopathology in the context of anti-CTLA-4 therapy [17, 125, 126].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · cites this paper as [125]
Gut microbiota correlated with the occurrence of immune-related adverse events (irAEs) induced by ICIs.
“gut microbiota also correlated with the occurrence of immune-related adverse events (irAEs) induced by ICIs.”
From Gut microbiota-mediated immunomodulation in tumor (2021) · cites this paper as [106]
In pre-clinical models, targeting specific bacterial taxa may reduce ICI-related toxicity.
“and have shown that targeting specific bacterial taxa may abrogate ICI-related toxicity in pre-clinical models17.”
From Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) · cites this paper as [17]
Patient 1 had an expansion of Bifidobacterium after FMT, which has been reported to reduce ICI-related toxicity in mice.
“Of note, the patient also showed an expansion of Bifidobacterium after FMT, which recently was reported to abrogate ICI-related toxicity in a murine model17”
From Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) · cites this paper as [17]
In patient 2, Blautia and Bifidobacterium increased after FMT, and these have been linked to less intestinal inflammation.
“In the second patient, there was a notable increase in the abundance of Blautia and Bifidobacterium species after FMT, which have been associated with reduced intestinal inflammation”
From Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) · cites this paper as [17]
Bifidobacterium treatment reduces weight loss following CTLA-4 blocking therapy in a standard colitis mouse model.
“Bifidobacterium treatment reduces weight loss following CTLA-4 blocking therapy in a standard colitis mouse model (83).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [83]
Bifidobacterium mitigates gut immunopathology without compromising the effects of immunotherapy.
“In addition, decreased secretion of inflammatory cytokines such as KC, IL-6, and CFS3 as observed with the same growth kinetics of the tumor, indicating that Bifidobacterium mitigates gut immunopathology without compromising on the effects of immunotherapy.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 28 · Cited by 223
- Authors
- Wang, F., Yin, Q., Chen, L., & Davis, M. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Stanford Medicine (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-12-18
- Volume
- 115
- Issue
- 1
- Pages
- 157-161
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5776803
- OpenAlex
- W2779119900
- Cited by
- 223
- References
- 28
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 32 · 2023: 38 · 2022: 31 · 2021: 29 · 2020: 30 · 2019: 17 · 2018: 6
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute (NA)
- Parker Foundation (NA)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- Bifidobacterium, probiotics, CTLA-4 blockade, immune checkpoint inhibitors, immune-related adverse events, autoimmunity, gut microbiota, cancer immunotherapy toxicity
- MeSH terms
- Animals, Bifidobacterium, Colitis, Mice, Transgenic, Vancomycin, Mice, Antibodies, Neutralizing, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
